On the other hand, 2DG as a glycolysis inhibitor can reduce the levels of IFN-γ, an important effector cytokine for the anti-tumor immune response, in both rodent models [53,54,55] and in vitro studies on human T cells from PBMCs [46,50,51,52] in line with the crucial role of glycolysis in IFN-γ secretion [46,48,49]. Here, IFNG is linked to neoplasm.